Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Exclusion Criteria

• •Any prior therapy for mantle cell non-Hodgkin lymphoma including radiation therapy; exception: patient may have undergone a splenectomy for diagnosis, cytopenia, or systematic splenomegaly
• •Active or uncontrolled infection
• •Any of the following cardiac conditions:
• •* Uncontrolled high blood pressure
• •* Unstable angina
• •* Active congestive heart failure
• •* Myocardial infarction =\< 6 months
• •* Serious uncontrolled cardiac arrhythmia
• •Known central nervous system (CNS) involvement
• •Any of the following:
• •* Pregnant women or women of reproductive ability who are unwilling to use effective contraception while taking the drug and for 12 months after stopping treatment
• •* Nursing women
• •* Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 12 months after stopping treatment
• •Medical or psychiatric conditions which, in the opinion of the investigator, make the patient a poor risk for participation
• •Known to be human immunodeficiency virus (HIV) positive; HIV testing is not required but should be done if clinically indicated; HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study
• •Concurrent malignancy =\< 5 years ago; exceptions: carcinoma in situ of the cervix, resected basal cell or squamous cell carcinomas of the skin, or prostate cancer that is in remission following a radical retropubic prostatectomy or radiation therapy; if there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer
• •Known hypersensitivity to rituximab or its components, or to murine proteins
• •Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
• •Prior treatment with an mTOR inhibitor
• •Autologous or allogeneic stem cell transplant planned as part of initial therapy
• •Receiving enzyme-inducing antiepileptic drugs (enzyme inducing anti-epileptic drugs \[EIAEDs\]; e.g., phenytoin, fosphenytoin, carbamazepine, oxcarbazepine, phenobarbital, or primidone); any other potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducer such as rifampin, glucocorticoids at greater than adrenal replacement levels, or St. John's wort; or receiving strong CYP3A4 inhibitors \* Note: if these agents are discontinued, temsirolimus therapy can begin \>= 7 days after discontinuation of such agent